On the evolutionary ecology of multidrug resistance in bacteria.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
05 2019
Historique:
received: 30 10 2018
accepted: 15 04 2019
revised: 23 05 2019
pubmed: 15 5 2019
medline: 19 11 2019
entrez: 15 5 2019
Statut: epublish

Résumé

Resistance against different antibiotics appears on the same bacterial strains more often than expected by chance, leading to high frequencies of multidrug resistance. There are multiple explanations for this observation, but these tend to be specific to subsets of antibiotics and/or bacterial species, whereas the trend is pervasive. Here, we consider the question in terms of strain ecology: explaining why resistance to different antibiotics is often seen on the same strain requires an understanding of the competition between strains with different resistance profiles. This work builds on models originally proposed to explain another aspect of strain competition: the stable coexistence of antibiotic sensitivity and resistance observed in a number of bacterial species. We first identify a partial structural similarity in these models: either strain or host population structure stratifies the pathogen population into evolutionarily independent sub-populations and introduces variation in the fitness effect of resistance between these sub-populations, thus creating niches for sensitivity and resistance. We then generalise this unified underlying model to multidrug resistance and show that models with this structure predict high levels of association between resistance to different drugs and high multidrug resistance frequencies. We test predictions from this model in six bacterial datasets and find them to be qualitatively consistent with observed trends. The higher than expected frequencies of multidrug resistance are often interpreted as evidence that these strains are out-competing strains with lower resistance multiplicity. Our work provides an alternative explanation that is compatible with long-term stability in resistance frequencies.

Identifiants

pubmed: 31083687
doi: 10.1371/journal.ppat.1007763
pii: PPATHOGENS-D-18-02106
pmc: PMC6532944
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1007763

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R015600/1
Pays : United Kingdom
Organisme : NIGMS NIH HHS
ID : U01 GM110721
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM088558
Pays : United States

Déclaration de conflit d'intérêts

ML has received consulting fees/honoraria from Merck, Pfizer, Affinivax, and Antigen Discovery, Inc and grant support not related to this paper from Pfizer and PATH Vaccine Solutions.

Références

Clin Microbiol Rev. 2006 Apr;19(2):382-402
pubmed: 16614254
J R Soc Interface. 2018 Jun;15(143):
pubmed: 29925579
Lancet. 2001 Apr 28;357(9265):1325-8
pubmed: 11343738
J Antimicrob Chemother. 2005 Jul;56(1):20-51
pubmed: 15914491
Evol Med Public Health. 2013 Jan;2013(1):65-74
pubmed: 24481187
BMJ. 2014 Sep 23;349:g5493
pubmed: 25249162
Nature. 2017 Nov 2;551(7678):45-50
pubmed: 29045390
Nat Genet. 2013 Jun;45(6):656-63
pubmed: 23644493
Science. 2011 Jan 28;331(6016):430-4
pubmed: 21273480
J R Soc Interface. 2010 Jun 6;7(47):905-19
pubmed: 19940002
Front Microbiol. 2017 Feb 17;8:246
pubmed: 28261193
J R Soc Interface. 2017 Aug;14(133):
pubmed: 28835542
Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):E11988-E11995
pubmed: 30559213
Pediatrics. 2003 Oct;112(4):862-9
pubmed: 14523178
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1075-1080
pubmed: 28096340
Evol Appl. 2015 Mar;8(3):273-83
pubmed: 25861385
PLoS Genet. 2009 Jul;5(7):e1000578
pubmed: 19629166
PLoS One. 2012;7(5):e38271
pubmed: 22693610
Int J Antimicrob Agents. 2007 Jun;29(6):630-6
pubmed: 17306965
Elife. 2017 Jul 25;6:
pubmed: 28742023
Nat Rev Genet. 2008 Jun;9(6):477-85
pubmed: 18427557
BMC Evol Biol. 2013 Aug 02;13:163
pubmed: 23914906
J Antimicrob Chemother. 2018 Feb 1;73(suppl_2):ii2-ii10
pubmed: 29490062
J Antimicrob Chemother. 2005 Nov;56(5):962-4
pubmed: 16150859
Curr Opin Pediatr. 2006 Feb;18(1):64-70
pubmed: 16470165
Microbiol Mol Biol Rev. 2015 Mar;79(1):101-16
pubmed: 25652543
Antimicrob Agents Chemother. 2008 Mar;52(3):813-21
pubmed: 18070961
Nat Ecol Evol. 2019 Mar;3(3):440-449
pubmed: 30742105
Emerg Infect Dis. 2012 Aug;18(8):1290-7
pubmed: 22840274
J Evol Biol. 2009 May;22(5):997-1003
pubmed: 19298493
PLoS Pathog. 2013 Feb;9(2):e1003134
pubmed: 23468619
Science. 2012 Mar 16;335(6074):1376-80
pubmed: 22383809
J Antimicrob Chemother. 2017 Jun 1;72(6):1818-1824
pubmed: 28333200
Nat Ecol Evol. 2017 Dec;1(12):1950-1960
pubmed: 29038424
PLoS Pathog. 2009 Jun;5(6):e1000476
pubmed: 19521509

Auteurs

Sonja Lehtinen (S)

Big Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

François Blanquart (F)

Big Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Center for Interdisciplinary Research in Biology (CIRB), Collège de France, CNRS, INSERM, PSL Research University, Paris, France.
IAME, UMR 1137, INSERM, Université Paris Diderot, Paris, France.

Marc Lipsitch (M)

Center for Communicable Disease Dynamics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States of America.
Departments of Epidemiology and Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, United States of America.

Christophe Fraser (C)

Big Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH